Potential role of immune modulation in the effective long-term control of HIV-1 infection

Journal of Biological Regulators and Homeostatic Agents

Volumn 16, Issue 1, 2002, Pages 83-90

  Rizzardi, G Paolo ^a   Lazzarin, A ^a   Pantaleo, G ^a  

^a MOLMED S P A   (Italy)

Author keywords

CsA; HAART; HIV; Immune based strategies; MMF; Primary and chronic infection

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ARTICLE; DISEASE COURSE; DRUG EFFECT; HELPER CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREACTIVITY; IN VIVO STUDY; INFECTION CONTROL; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MONKEY; NONHUMAN; PATHOGENESIS; VIROLOGY; VIRUS INHIBITION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0036255472     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (95)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Declines in AIDS incidence and deaths in the USA: A signal change in the epidemic
3. HIV-1 protease inhibitors. A review for clinicians
4. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior anti-retroviral therapy
5. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
6. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS Trial
7. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
8. Human immunodeficiency virus drug therapy and virus load
9. + lymphocyte count improves assessment of antiretroviral therapeutic response
10. + lymphocytes as prognostic markers of HIV-1 infection
11. + lymphocyte counts predict both response to anti-retroviral therapy and therapeutic failure
12. Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count
13. When to start highly active antiretroviral therapy in chronically HIV-infected patients: Evidence from the ICONA study
14. The immunopathogenesis of HIV-1 infection
15. Pathogenesis of HIV-1 infection
16. Viral dynamics in HIV-1 infection
17. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection
18. Latent reservoirs of HIV: Obstacles to the eradication of virus
19. Presence of an inducible HIV-1 latent reservoir during highly active anti-retroviral therapy
20. Identification of a reservoir for HIV-1 in patients on highly active anti-retroviral therapy
21. + T-cell renewal in early HIV-1 infection: Effect of highly active antiretroviral therapy
22. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans
23. T cell regeneration in HIV-infected subjects under highly active antiretroviral therapy
24. Long-term kinetics of T cell production in HIV-infected subjects treated with highly active antiretroviral therapy
25. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
26. Limits to potent antiretroviral therapy
27. Abnormal fat distribution and use of protease inhibitors
28. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
29. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
30. Mitochondrial toxicity induced by nucleoside-analogue reverse- transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
31. Adverse effects of antiretroviral therapy
32. Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia
33. HIV-protease inhibitors
34. Images in clinical medicine. Buffalo hump in a patient with the acquired immunodeficiency syndrome
35. Hit HIV-1 hard, but only when necessary
36. HIV treatment failure: Testing for HIV resistance in clinical practice
37. Public health implications of antiretroviral therapy and HIV drug resistance
38. Efficacy of adding indinavir to previous reverse transcriptase nucleoside analogues in relation to genotypic and phenotypic resistance development in advanced HIV-1-infected patients
39. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia
40. + T cells during primary HIV-1 infection
41. Therapeutic perspectives in HIV-1 infection from recent advances in HIV- 1 pathogenesis: It is time to move on
42. Other approaches to combat HIV-1 infection
43. Fidelity of HIV-1 reverse transcriptase
44. The accuracy of reverse transcriptase from HIV-1
45. + cells per cubic millimeter
46. Immunological and virological responses in HIV-1-infected adults at early stage of established infection treated with highly active antiretroviral therapy
47. The moving target: Mechanisms of HIV persistence during primary infection
48. Changes in thymic function with age and during the treatment of HIV infection
49. Strategies for immune restoration
50. Viral dynamics in human immunodeficiency virus type 1 infection
51. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
52. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation
53. Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV
54. Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy
55. Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA
56. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy
57. Effects of mycophenolic acid on human immunodeficiency virus infection in vitro and in vivo
58. How immune-based interventions can change HIV therapy
59. Treatment of primary human immunodeficiency virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to aids
60. Immune control of HIV-1 after early treatment of acute infection
61. + T lymphocytes
62. Highly active anti-retroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: Results of the ANRS 053 trial
63. Acute human immunodeficiency virus type 1 infection
64. Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: Implications for antiviral therapy
65. Biological and virologic characteristics of primary HIV infection
66. + T cell responses associated with control of viremia
67. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia
68. Plasma levels of soluble CD30, tumour necrosis factor (TNF)-alpha and TNF receptors during primary HIV-1 infection: Correlation with HIV-1 RNA and the clinical outcome
69. Clinical and epidemiologic features of primary HIV infection
70. A controlled trial of zidovudine in primary human immunodeficiency virus infection
71. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage
72. AIDS as immune system activation: A model for pathogenesis
73. Immune changes in HIV-1 infection: Significant correlations and differences in serum markers and lymphoid phenotypic antigens
74. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1
75. +CD25- T cell population
76. The initial immune response to HIV and immune system activation determine the outcome of HIV disease
77. Tracking HIV during disease progression
78. New concepts in the immunopathogenesis of HIV infection
79. Effects of cyclosporin on T-cell subsets in human immunodeficiency virus disease
80. Cyclosporine-induced deterioration in patients with AIDS
81. Cyclosporin A modulation of early virologic and immunologic events during primary simian immunodeficiency virus infection in rhesus monkeys
82. Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation
83. Cyclophilin a modulates processing of human immunodeficiency virus type 1 p55Gag: Mechanism for antiviral effects of cyclosporin A
84. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease
85. Skewed maturation of memory HIV-specific CD8 T lymphocytes
86. The role of chemokine receptors in primary, effector, and memory immune responses
87. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
88. Factors influencing T-cell turnover in HIV-1-seropositive patients
89. + T cells
90. HIV-1 entry into quiescent primary lymphocytes: Molecular analysis reveals a labile, latent viral structure
91. Accumulation of human immunodeficiency virus-specific cytotoxic T lymphocytes away from the predominant site of virus replication during primary infection
92. + T cell demographics and dynamics in lymphatic tissues
93. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy
94. Taking aim at HIV replication